Immunogenicity of 2 vs 3 Doses of the Quadrivalent Human Papillomavirus Vaccine in Girls Aged 9 to 13 Years After 60 Months

• Autores: Gina Ogilvie, Marc Dionne, Chantal Sauvageau
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 317, Nº. 16, 2017, págs. 1687-1688
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Human papillomavirus (HPV) vaccines were originally approved with 3-dose schedules. However, 2 doses of HPV vaccine have been recommended1 for girls younger than 15 years based on antibody response at 36 months,2,3 although continued research on the duration of antibody persistence was advised. We report antibody response at 60 months after 2 doses of quadrivalent HPV vaccine.